EYPT Stock - EyePoint Pharmaceuticals, Inc.
Unlock GoAI Insights for EYPT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $43.27M | $46.02M | $41.40M | $36.94M | $34.44M |
| Gross Profit | $39.56M | $41.39M | $33.08M | $28.76M | $28.61M |
| Gross Margin | 91.4% | 89.9% | 79.9% | 77.9% | 83.1% |
| Operating Income | $-145,854,000 | $-75,067,000 | $-99,637,000 | $-55,276,000 | $-37,290,000 |
| Net Income | $-130,870,000 | $-70,795,000 | $-102,254,000 | $-58,417,000 | $-45,394,000 |
| Net Margin | -302.4% | -153.8% | -247.0% | -158.1% | -131.8% |
| EPS | $-2.32 | $-1.82 | $-2.74 | $-2.03 | $-3.54 |
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 17th 2025 | RBC Capital Mkts | Initiation | Outperform | $28 |
| January 7th 2025 | Citigroup | Initiation | Buy | $33 |
| October 16th 2024 | Scotiabank | Initiation | Sector Outperform | - |
| August 28th 2024 | Jefferies | Initiation | Buy | $15 |
| January 22nd 2024 | JP Morgan | Initiation | Overweight | $35 |
| November 2nd 2023 | Mizuho | Initiation | Buy | $20 |
| April 21st 2023 | Robert W. Baird | Initiation | Outperform | $33 |
| July 7th 2022 | Chardan Capital Markets | Initiation | Buy | $21 |
Earnings History & Surprises
EYPTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Mar 4, 2026 | $-0.74 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.77 | $-0.85 | -10.4% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-0.67 | $-0.85 | -26.9% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-0.65 | $-0.65 | 0.0% | = MET |
Q1 2025 | Mar 5, 2025 | $-0.54 | $-0.64 | -18.5% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.48 | $-0.54 | -12.5% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.55 | $-0.58 | -5.5% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.34 | $-0.55 | -61.8% | ✗ MISS |
Q1 2024 | Mar 7, 2024 | $-0.60 | $-0.33 | +45.0% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $-0.62 | $-0.33 | +46.8% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $0.41 | $-0.61 | -248.8% | ✗ MISS |
Q2 2023 | May 3, 2023 | $-0.65 | $-0.56 | +13.8% | ✓ BEAT |
Q1 2023 | Mar 2, 2023 | $-0.63 | $-0.61 | +3.2% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-0.70 | $-0.49 | +30.0% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-0.57 | $-0.52 | +8.8% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-0.50 | $-0.52 | -4.0% | ✗ MISS |
Q1 2022 | Mar 3, 2022 | $-0.50 | $-0.59 | -18.0% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $-0.47 | $-0.58 | -23.4% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $-0.45 | $-0.35 | +22.2% | ✓ BEAT |
Latest News
The Independent Data Safety Monitoring Committee Completed Its Second Scheduled Review Of Eyepoint Pharmaceuticals' Ongoing Phase 3 Program Of Duravyu For Wet Age-related Macular Degeneration, No Changes In Protocol Recommended For LUGANO and LUCIA Trials
📈 PositiveEyepoint Pharmaceuticals May Offer & Sell Up To $200M Common Stock Offering With Cantor Fitzgerald
➖ NeutralRBC Capital Maintains Outperform on EyePoint Pharmaceuticals, Raises Price Target to $39
📈 PositiveEyePoint Pharmaceuticals Q3 EPS $(0.85) Misses $(0.79) Estimate, Sales $966.000K Miss $3.329M Estimate
📉 NegativeEyePoint Pharmaceuticals shares are trading lower after the company announced the pricing of a 11 million share offering at $12 each.
📉 NegativeReported Earlier, EyePoint Prices 11M Shares At $12 Each Plus 1.5M Pre-Funded Warrants To Support Clinical Pipeline Expansion
➖ NeutralEyePoint Pharmaceuticals Announces $150M Proposed Public Offering of Common Stock
➖ NeutralEyePoint Pharmaceuticals Initiates Pivotal Phase 3 Program For DURAVYU To Treat Diabetic Macular Edema; Expects First Patient Dosage In Q1 2026
📈 PositiveFrequently Asked Questions about EYPT
What is EYPT's current stock price?
What is the analyst price target for EYPT?
What sector is EyePoint Pharmaceuticals, Inc. in?
What is EYPT's market cap?
Does EYPT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to EYPT for comparison